Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 2019 Mar;25(3):e89-e97
Date
11/09/2018Pubmed ID
30408566Pubmed Central ID
PMC6445685DOI
10.1016/j.bbmt.2018.11.001Scopus ID
2-s2.0-85057956613 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
The second annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 7, 2017, at the American Society of Hematology (ASH) meeting. During this workshop, investigators from around the world presented their latest research involving assessment of minimal residual disease (MRD) and immune profiling (IP) in myeloma. This document summarizes the workshop presentations as well as relevant ASH abstracts and focuses on the regulatory issues involved in the integration of MRD and IP assessment in clinical trial design and practice.
Author List
Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PLMESH terms used to index this publication - Major topics in bold
Bone Marrow TransplantationClinical Trials as Topic
Congresses as Topic
Education
Humans
Immunologic Factors
Multiple Myeloma
Neoplasm, Residual
Societies, Scientific
